Our Innovation Center in Bangalore houses Asia’s largest private sector pharmaceutical research facility, where 200+ scientists work across 15 therapeutic areas to address unmet medical needs.
Developing targeted therapies with reduced side-effect profiles
Novel GLP-1 analogs with weekly dosing convenience
Next-generation CNS drugs with improved blood-brain barrier penetration
First biosimilar approved for rheumatoid arthritis in 6 emerging markets
Novel extended-release antipsychotic with 40% fewer side effects
© 2026 Leiha Pharmaceuticals. All right reserved.